In a nutshell This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin...
Read More
In a nutshell This study looked at the side effects of dapagliflozin (Farxiga) for patients with type 2 diabetes (T2D). It found that dapagliflozin was well tolerated and led to less kidney injury for patients with T2D. Some background T2D is a disorder that causes high levels of glucose (sugar) in the blood. Over time, high blood glucose can cause a...
Read MoreIn a nutshell This trial is examining the effectiveness of tirzepatide compared to insulin glargine in patients with type 2 diabetes who are also at high risk for heart disease. The main outcome to be measured will be a change in HbA1c (a blood test that measures average blood sugar levels in the past 3 months) over 52 weeks. The details In type 2...
Read More
In a nutshell This study evaluated the risk of genital infections in patients with Type 2 diabetes (T2D) treated with SGLT2 (sodium-glucose cotransporter 2) inhibitors. This study concluded that this therapy was associated with a 3-fold higher risk of genital infections in these patients. Some background SGLT2 inhibitors help the kidneys remove...
Read More
